Diabetes management programs can be delivered digitally or in a traditional in-person setting, but there are benefits and drawbacks to each, explained Neal Kaufman, MD, founder and chief medical officer of Canary Health.
Diabetes management programs can be delivered digitally or in a traditional in-person setting, but there are benefits and drawbacks to each, explained Neal Kaufman, MD, founder and chief medical officer of Canary Health.
Transcript (slightly modified)
What are the advantages of digital delivery of a chronic disease management program, compared with an in-person program?
I think they’re both very important. They’re both excellent ways of bringing research-proven approaches to help people self-manage their conditions. Digital has certain advantages over in-person, and in-person has advantages over digital.
Digital is ubiquitous, 24/7, the person doesn’t need to get in their car to get to the appointment, they can access it from the privacy of their home, they can come on for 5 or 10 minutes if that’s all they have that day, or they can spend an hour or longer if need be. It identifies and helps people who don’t like to join groups. Many people are not happy with that approach; they want to be anonymous in their conversations.
In-person is in-person, and it allows you to have a more intimate relationship with individuals who come to your group. It has benefits where individuals are able to share and have that direct social support. Digital provides indirect social support, and depending on the individual, some approaches work better than others.
In-person has a challenge, in that you have to get people to show up at the same time, at the same place, an hour a week or more depending on the program, and that can have some significant logistics challenges.
So, I actually believe that the future will have combined approaches where individuals will be given the choice between a digital delivery of that program, in this case a diabetes prevention program or a chronic disease self-management program, and also in-person delivery of those same programs.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More